Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoschisin is a soluble, cell-surface protein crucial for the structural and functional maintenance of the retina. Encoded by the RS1 gene, it is primarily expressed by retinal bipolar cells and photoreceptors. Retinoschisin forms paired octamer rings and mediates cell-to-cell adhesion. Mutations in RS1 cause X-linked juvenile retinoschisis (XLRS), a progressive degenerative disease characterized by the formation of cystic cavities within the retina, separation of retinal layers, and ultimately, vision loss. It maintains retinal architecture by binding to plasma membranes of photoreceptor and bipolar cells, facilitating tight cellular organization in the retina.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoschisin (RS1).